The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immunological correlates of response and immune-mediated toxicity in checkpoint inhibitor (ICI)-treated metastatic urothelial carcinoma (mUC) patients (pts).
 
Amanda Nizam
No Relationships to Disclose
 
Alice Tzeng
No Relationships to Disclose
 
Wei Wei
No Relationships to Disclose
 
Patricia A. Rayman
No Relationships to Disclose
 
Paul G. Pavicic
No Relationships to Disclose
 
Vladimir Makarov
Patents, Royalties, Other Intellectual Property - EP3090066A2: Determinants of cancer response to immunotherapy.
 
Ivan Juric
No Relationships to Disclose
 
Tyler Alban
No Relationships to Disclose
 
Shadi Swaidani
No Relationships to Disclose
 
Iris Yeong-Fung Sheng
No Relationships to Disclose
 
Timothy D. Gilligan
Travel, Accommodations, Expenses - Dendreon
 
Shilpa Gupta
Stock and Other Ownership Interests - Moderna Therapeutics; Nektar
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - AVEO; EMD Serono; Gilead Sciences; Guardant Health; Loxo/Lilly; Merck; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Janssen Oncology
 
C. Marcela Diaz-Montero
No Relationships to Disclose
 
Moshe Chaim Ornstein
Consulting or Advisory Role - AVEO; Bristol Myers Squibb Foundation; Eisai; Exelixis; Merck; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Exelixis
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Exelixis